Member Info for sellonnews

Good afternoon, nennyb It appears that the slow walk-down from 0.54p {April 24) is continuing, and could go much lower. . .

https://twitter.com/mysquar Are you sure about only holding until 5p/6p? . . GL .

nennyb, You are most welcome, but is a chart needed to say that a price will rise on good news and fall on bad news, or predict when that news will arrive? . .

The blue line is the price. " A green volume bar means that the stock closed higher on that day verses the previous day’s close. A red volume bar means that the stock closed lower on that day compared to the previous day’s close. A black volume bar means that the stock closed at the same price that day as it did the day before" . .

Blue, not green, is a buy and just black is the mid-price sale, on LSE. Apologies for any confusion. . .

https://www.stockmarketeye.com/blog/reading-colors-in-stock-charts-green-and-red-explained/ On individual trades, red is a sell, green is a buy, and blue/black indicates it could be either as the trade was at the mid-price, between bid and offer. . .

PS For information only The investment (not current value) in CPX is higher than for MYSQ, with a same target price. . .

No time frame, just patience lol There again, how long before the broker target of 21p is attained? . .

Hi nennyb Been in MYSQ for a while (£100k-plus invested there) but holding for a higher price, 8p or 9p, before even thinking about selling any. Unlike yourself, investment in ECHO is £nil as that overhang of 0.068p shares is still a concern, and will remain even after the consolidation and market updates. Might consider ECHO in the future, but there appears to be companies with better fundamentals and growth prospects going forward imho. Three current holdings, CPX, EQT, and ZEN, are belived to meet those criteria, but ECHO might be better than all of them, who knows? Obviously, those three are personal preferences and not intended as investment advice in any way, shape, or form - always DYOR. Good luck . .

Good to see you over on MYSQ . . GL .

What is "approximately $80.0 million"? . .

Have you noticed anything about the share price since April 24 (0.54p)? Look at the general trend - it appears to being slowly walked down, and if this pattern continues, where will it stop, 0.4p, 0.3p, 0.2p? Just an observation. . GL .

It helps to remember what one has said, "Its just things like this that are holding me back from investing in this stock, i would verry hapilly invest up to £500" vs "but i like all of you am heavily invested in this company and will draw a poster myself with crayons" Please refrain from eating said crayons as they can have an adverse effect in so many ways. . .

WoodenChair Had you done but a scintilla of research you would be fully aware that any new medicine has to complete three phases of testing before it is allowed to be sold. It is also apparent that this information (March 31 2017) might have escaped your in-depth research: "Following the development of commercially viable formulations, Verona Pharma plans to commence pre-clinical studies with the DPI and MDI formulations and may also explore the potential use of the formulation for the treatment of asthma and other respiratory diseases" Given your stated frustrations, and by way of amelioration, it is humbly suggested that a pack of Crayola could be used to design some posters for forwarding to the directors. Wishing you every success in that endeavour. (Perhaps, you could also post them online for appraisal?). In order that there are no further distractions it is hoped that others may respond to your sagacity as I shall refrain hereonin. . .

Absolutely! Unfortunately..... https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk Pesky regulations, again! . .

Pesky regulations! Before a new drug can be marketed it must satisfy the FDA, "Drug companies seeking to sell a drug in the United States must first test it." https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm The testing stages: https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm http://www.veronapharma.com/news-and-media/#news-and-media-press-releases It would therefore appear that there will be no marketing until all trials are completed and FDA approval granted - at least two years from now, and that's a long time to be frustrated. . .

I respectfully refer to my prior comment, noting, "RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, currently in development for the treatment of chronic obstructive pulmonary disease and cystic fibrosis" Please note, "currently in development", that is, it is still undergoing testing and not available. . .

Your (sic) fast lol . .

Better to remain silent and be thought a fool than to speak and to remove all doubt. . .

It might be advisable to keep a very close eye on the share price over the coming days given the way it was taken up earlier for it subsequently to drop - the joys of MMs . .